Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 ...

The therapy targets mast cells by inhibiting receptor tyrosine kinase KIT, crucial for mast cell function and survival. Significant improvements in UAS7 and quality of life were observed.

Zhejiang Jingke Pharmaceuticals Co. Ltd. has identified mast/stem cell growth factor receptor kit (KIT; c-Kit; CD117) inhibitors reported to be useful for the treatment of cancer, neurodegeneration, ...

Shares of Jasper Therapeutics rose after the company disclosed what it called positive data from a recent trial of its treatment for chronic mast cell diseases. The stock climbed 13%, to $6.32, in ...

The granted patent, titled "Targeting KIT with Splice Switching Oligonucleotides to Induce Apoptosis of Mast Cells," protects Hoth's novel approach of using splice-switching oligonucleotides (SSOs) to ...